Gengler, Simon, McClean, Paula L., McCurtin, Ruth, Gault, Victor and Holscher, Christian (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. NEUROBIOLOGY OF AGING, 33 (2). pp. 265-276. [Journal article]
Full text not available from this repository.
Diabetes is a risk factor for Alzheimer's disease. We tested the effects of Val(8) GLP-1, an enzyme-resistant analogue of the incretin hormone glucagon-like peptide 1 originally developed to treat diabetes in a mouse model of Alzheimer's disease that expresses mutated amyloid precursor protein (APP) and presenilin-1. We tested long term potentiation (LTP) of synaptic plasticity, inflammation response, and plaque formation. Val(8) GLP-1 crosses the blood-brain barrier when administered via intraperitoneal injection. Val(8) GLP-1 protected LTP in 9- and 18-month-old Alzheimer's disease mice when given for 3 weeks at 25 nmol/kg intraperitoneally. LTP was also enhanced in 18-month-old wild type mice, indicating that Val(8) GLP-1 also ameliorates age-related synaptic degenerative processes. Paired-pulse facilitation was also enhanced. The number of beta-amyloid plaques and microglia activation in the cortex increased with age but was not reduced by Val(8) GLP-1. In 18-month-old mice, however, the number of Congo red positive dense-core amyloid plaques was reduced. Treatment with Val(8) GLP-1 might prevent or delay neurodegenerative processes. (C) 2012 Elsevier Inc. All rights reserved.
|Item Type:||Journal article|
|Faculties and Schools:||Faculty of Life and Health Sciences > School of Biomedical Sciences|
Faculty of Life and Health Sciences
|Research Institutes and Groups:||Biomedical Sciences Research Institute > Genomic Medicine|
Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Diabetes
|Deposited By:||Dr Nigel Irwin|
|Deposited On:||28 Mar 2012 15:07|
|Last Modified:||28 Mar 2012 15:07|
Repository Staff Only: item control page